MétaCan
Menu
Back to cohort
Record W4404564918 · doi:10.51731/cjht.2024.1029

Ciltacabtagene Autoleucel (Carvykti)

2024· article· en· W4404564918 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2024
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsnot available
Fundersnot available
KeywordsLenalidomideMedicineChimeric antigen receptorDrugRefractory (planetary science)Multiple myelomaDiseaseThalidomideInternal medicineOncologyIntensive care medicinePharmacologyImmunotherapyCancer

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Carvykti should be reimbursed by public drug plans for the treatment of adult patients with multiple myeloma (MM), who have received 1 to 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and whose disease is refractory to lenalidomide if certain conditions are met. Carvykti should only be covered to treat patients aged 18 years or older with documented diagnosis of MM, who have received 1 to 3 prior lines of therapy, and have a good performance status, as determined by a specialist. Carvykti should not be reimbursed for the treatment of patients whose MM is affecting their central nervous system. It should also not be reimbursed for patients who have previously received any treatment that targets B-cell maturation antigen (BCMA). Carvykti should only be reimbursed if it is prescribed and administered by clinicians with expertise in the treatment of MM at specialized centres with adequate infrastructure, resources, and expertise to facilitate treatment with chimeric antigen receptor (CAR) T-cell therapy, and the cost of Carvykti is reduced.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.969
Threshold uncertainty score0.997

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.356
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicCAR-T cell therapy researchFrench-language works237,207